Combination strategies in myelodysplastic syndromes

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

(2011) P. Fenaux et al.   BLOOD

Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome

(2011) Jose Ramon Gonzalez-Porras et al.   CANCER

Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes

(2011) Guillermo Garcia-Manero et al.   JOURNAL OF CLINICAL ONCOLOGY

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

(2011) Michael Lübbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of Lower-Risk Myelodysplastic Syndromes:The Art and Evidence

(2011) Rami S. Komrokji et al.   Current Hematologic Malignancy Reports

Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes

(2010) Mikkael A. Sekeres et al.   AMERICAN JOURNAL OF HEMATOLOGY

Are we nearer to curing patients with MDS?

(2010) Mikkael A. Sekeres   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

(2010) H. M. Kantarjian et al.   BLOOD

Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept

(2010) Bart L. Scott et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia

(2010) Mikkael A. Sekeres et al.   CANCER

Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes

(2010) Mikkael A. Sekeres et al.   JOURNAL OF CLINICAL ONCOLOGY

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Advancements in the molecular pathogenesis of myelodysplastic syndrome

(2009) Pearlie K Epling-Burnette et al.   CURRENT OPINION IN HEMATOLOGY

Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes

(2009) Roger M. Lyons et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia

(2009) Hagop Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes

(2009) Lanlan Shen et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML

(2008) Y. Jiang et al.   BLOOD

Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy

(2008) Elaine M. Sloand et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

(2008) David J Kuter et al.   LANCET